Last reviewed · How we verify
TQB3454
At a glance
| Generic name | TQB3454 |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma. (PHASE3)
- A Study of TQB3454 Tablets in Patients With Blood Tumors (PHASE1, PHASE2)
- A Clinical Trial of TQB3454 Tablets in Healthy Adult Subjects (PHASE1)
- A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TQB3454 CI brief — competitive landscape report
- TQB3454 updates RSS · CI watch RSS
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. portfolio CI